Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 24;72:103589. doi: 10.1016/j.ebiom.2021.103589

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s)

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig 1 — Antibody levels and neutralisation in convalescent COVID-19 patients and uninfected participants prior to and after first and second vaccine dose. The overarching line represents the comparison of both the previous infected groups after the first vaccination with the non-infected group after the second vaccination. The number of patients (n) in the legend is for the prior infectious group on “21 days after vaccination” and for the non-infectious group on “28 days after second vaccination”. a: Serum IgG binding levels to SARS-CoV-2 spike protein. The number of participants with a recent infection, earlier infection and no previous infection pre-vaccination were: n = 19, n = 20 and n = 84, respectively, at 21 days after the first vaccination: n = 17, n = 17, n = 82, respectively, and at 28 days after the second vaccination: n = 18, n = 19 and n = n = 73, respectively. Group medians were compared using the Mann-Whitney-U test. There was no significant difference at 21 days after the first vaccination and at 28 days after the second vaccination between the recent infection and the earlier infection groups, p = 0•11 and p = 0•13, respectively. The results of the recently infected and earlier infected groups at 21 days after the first vaccination were significantly different from the non-infected group at 28 days after the second vaccination, p = 0•003 and p < 0•001 respectively. MFI: Mean Fluorescence Intensity. b: Serum neutralisation of SARS-CoV-2 pseudovirus, with a lower limit of detection of 100 ID₅₀. The number of participants with a recent infection, earlier infection and no previous infection pre-vaccination were: n = 16, n = 20 and n = 6, respectively, at 21 days after the first vaccination: n = 18, n = 19, n = 82, respectively, and at 28 days after the second vaccination: n = 18, n = 18 and n = 51, respectively. Group medians were compared using the Mann-Whitney-U test. There was no significant difference at 21 days after the first vaccination and at 28 days after the second vaccination between the recently infected and earlier infected groups, p = 0•26 and p = 0•15, respectively. The recently infected and the earlier infected groups at 21 days after the first vaccination were significantly different from the non-infected group at 28 days after the second vaccination, p < 0•001 and p < 0•001 respectively. ID₅₀: 50% Inhibitory Dilution.

Fig 1 — Antibody levels and neutralisation in convalescent COVID-19 patients and uninfected participants prior to and after first and second vaccine dose. The overarching line represents the comparison of both the previous infected groups after the first vaccination with the non-infected group after the second vaccination. The number of patients (n) in the legend is for the prior infectious group on “21 days after vaccination” and for the non-infectious group on “28 days after second vaccination”. a: Serum IgG binding levels to SARS-CoV-2 spike protein. The number of participants with a recent infection, earlier infection and no previous infection pre-vaccination were: n = 19, n = 20 and n = 84, respectively, at 21 days after the first vaccination: n = 17, n = 17, n = 82, respectively, and at 28 days after the second vaccination: n = 18, n = 19 and n = n = 73, respectively. Group medians were compared using the Mann-Whitney-U test. There was no significant difference at 21 days after the first vaccination and at 28 days after the second vaccination between the recent infection and the earlier infection groups, p = 0•11 and p = 0•13, respectively. The results of the recently infected and earlier infected groups at 21 days after the first vaccination were significantly different from the non-infected group at 28 days after the second vaccination, p = 0•003 and p < 0•001 respectively. MFI: Mean Fluorescence Intensity. b: Serum neutralisation of SARS-CoV-2 pseudovirus, with a lower limit of detection of 100 ID₅₀. The number of participants with a recent infection, earlier infection and no previous infection pre-vaccination were: n = 16, n = 20 and n = 6, respectively, at 21 days after the first vaccination: n = 18, n = 19, n = 82, respectively, and at 28 days after the second vaccination: n = 18, n = 18 and n = 51, respectively. Group medians were compared using the Mann-Whitney-U test. There was no significant difference at 21 days after the first vaccination and at 28 days after the second vaccination between the recently infected and earlier infected groups, p = 0•26 and p = 0•15, respectively. The recently infected and the earlier infected groups at 21 days after the first vaccination were significantly different from the non-infected group at 28 days after the second vaccination, p < 0•001 and p < 0•001 respectively. ID₅₀: 50% Inhibitory Dilution.